

**OFFICIAL**

- 9/22/01
39. (New) A method according to claim 38 wherein the mammal is a human.
40. (New) A method according to claim 38 wherein the protozoa is *Plasmodium falciparum*.
- Sub D2  
43  
Sub 44
41. (New) A method according to claim 38 wherein NO is administered by inhalation to increase systemic NO levels or NO effect.
42. (New) A method according to claim 38 wherein the agent is a NO donor.
43. (New) A method according to claim 38 wherein the NO modifying agent results in the formation within the circulatory system and/or tissues of NO in the form of a compound of formula:

**BEST AVAILABLE COPY**

C1  
COND

wherein R is an NO releasing, delivering or transferring moiety such as an amino acid, peptide, polypeptide, protein, enzyme, amine, glycolipid, polysaccharide or a chemical derivative thereof.

44. (New) A method according to claim 38 where the NO donor results in the formation of or is itself a R'-S-NO compound where the moiety R'-S- is derived from the corresponding thiol, R'-SH.
- Sub 45
45. (New) A method according to claim 38 wherein the NO modifying agent includes or is derived from the group consisting of cysteinylglycine, cysteine, cysteamine, lipoic acid, dithiothreitol, glutathione, L-arginine, penicillamine, N-acetyl-penicillamine, N-acetylcysteine, albumin, tissue plasminogen activator, streptokinase, a cytokine or an antagonist or agonist of a cytokine (eg. an antibody to a cytokine or soluble receptor for a cytokine or a fragment of a cytokine or a cytokine binding protein) an interferon (IFN) including IFN $\alpha$ , IFN $\beta$ , IFN $\gamma$ , a growth factor including granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), an interleukin (IL) including IL-1 to IL-13, haemoglobin and cathepsin B.